Laboratory data, medical therapy and adverse events at 1 year
| Health education group (n=117) | Exercise intervention group (n=118) | P value | |
| Laboratory data | |||
| White blood cells, (μ/µL) | 6.5±2 | 6.5±2 | 0.9 |
| Haemoglobin, (g/dL) | 12±2 | 12.5±2 | 0.06 |
| Creatinine clearance, (mL/min) | 58±19 | 60±18 | 0.04 |
| Albumin, (g/dL) | 3.5 (3.1–3.7) | 3.6 (3.3–4) | 0.2 |
| Low-density lipoprotein, (mg/dL) | 80±30 | 72±21 | 0.02 |
| C reactive protein, (mg/dL) | 0.51 (0.2–3) | 0.5 (0.2–3.1) | 0.8 |
| Brain natriuretic peptide, (ng/L) | 115 (60–251) | 110 (55–230) | 0.7 |
| Medical therapy, n (%) | |||
| Aspirin | 112 (96) | 115 (97) | 0.9 |
| P2Y12 inhibitor | 81 (69) | 93 (79) | 0.7 |
| Compliance to 1-year dual antiplatelet (DAPT) regimen | 78 (66) | 90 (76) | 0.09 |
| Beta-blocker | 70 (60) | 71 (60) | 0.9 |
| ACE inhibitor | 70 (60) | 73 (62) | 0.8 |
| A2R antagonist | 31 (26) | 30 (25) | 0.9 |
| Statin | 99 (85) | 100 (85) | 0.9 |
| Loop diuretic | 45 (38) | 22 (19) | 0.1 |
| Adverse events, no. (%) | |||
| All-cause death | 3 (1) | 1 (1) | 0.4 |
| Cardiac death | 3 (2) | 1 (1) | 0.4 |
| All-cause hospitalisation for: | 21 (18) | 12 (10) | 0.08 |
| ACS | 6 (5) | 4 (3) | 0.7 |
| CVA | 0 (0) | 1 (1) | 0.9 |
| HF | 11 (9) | 3 (3) | 0.05 |
| CCS | 2 (2) | 1 (1) | 0.7 |
| Infection | 4 (3) | 2 (2) | 0.6 |
| Surgery | 1 (1) | 1 (1) | 0.9 |
| CD and hospitalisation for cardiovascular cause | 20 (17) | 9 (8) | 0.04 |
ACS, acute coronary syndrome; A2R, angiotensin 2 receptor; CCS, chronic coronary syndrome; CD, cardiac death; CVA, cerebrovascular accident; HF, heart failure.